25th Anniversary Of Anti-AIDS Drugs
Elsevier journal Antiviral Research publishes milestone Special Issue
Amsterdam, March 3, 2010 – Elsevier, the world-leading publisher of scientific, technical and medical information products and services, released a special issue of the journal Antiviral Research, marking the 25th anniversary of antiretroviral drug development. The guest editors, José Esté from Hospital Germans Trias i Pujol, Barcelona, Spain and Tomas Cihlar, from Gilead sciences Inc., CA, USA were able to attract the key players in the field who all contributed a variety of review articles to this special issue, thereby creating a must-read for anybody interested in AIDS treatment.
In his review article, introducing this special issue of Antiviral Research, Samuel Broder from the Celera Corporation in Alameda, CA, USA, describes how in the last 25 years, HIV-1 has gone from being an ‘inherently untreatable’ infectious agent to one eminently susceptible to a range of approved therapies. In the late 1980s his group, then at the National Cancer Institute, played a key role in the discovery and development of the first generation of antiretroviral agents.
Physicians now have approximately 30 antiretroviral products, formulated either alone or in combination, to treat patients with human immunodeficiency virus (HIV-1), the pathogenic retrovirus which causes the acquired immunodeficiency syndrome (AIDS) and related conditions. Most are oral medicines, administered on convenient schedules. Several have been specially formulated as fixed-dose, generic-drug combinations for even greater utility in resource-poor nations.
In 2010 the journal Antiviral Research will celebrate its 30th anniversary by organizing an Antivirals Congress from 7-9 November 2010 in Amsterdam, the Netherlands (www.antivirals.elsevier.com). Floris de Hon, the Executive Publisher of the journal stated: “The guest editors and various authors of this milestone publication on anti-AIDS drugs will present at the Congress, which promises to serve as an interface between academics, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals”.
# # #
Notes to Editors:
To receive a copy of Antiviral Research, Volume 85, Issue 1, January 2010; Special Issue – Twenty-five Years of Antiretroviral Drug Development: Progress and Prospects (Guest editors José Esté and Tomas Cihlar), please contact the Marketing Communication Manager of Antiviral Research at firstname.lastname@example.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligenceand ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.Media Contact:
+44 1865 843 181